KELUN PHARMA(SZ:002422)2023-09-01 03:56Sales Performance - The company's infusion revenue for the first half of 2023 reached approximately 50.27 billion RMB, a year-on-year increase of 14% [2] - Non-infusion revenue was around 18 billion RMB, with traditional drugs contributing 10.2 billion RMB [2] - The new generic drug revenue was 8.1 billion RMB, reflecting a slight decline due to price reductions from centralized procurement [2] Research and Development - R&D expenses for the first half of 2023 totaled 4.9 billion RMB, with a focus on key pipelines and competitive projects [2] - The company expects to maintain approximately 30 new approvals annually in the coming years based on current application inventory and project progress [3] Market Strategy - The company is expanding its product pipeline in critical areas such as infectious diseases, central nervous system, and anesthesia [3] - The closed infusion system's market share is projected to increase by 2.5 billion bags in 2023, with ongoing market development efforts [3] Product Development - The dual-chamber bag production capacity is expected to ramp up by the end of 2023, with new products entering the National Medical Insurance negotiation process [4] - The company plans to introduce over 20 new products, including various antibiotics, in the near future [4] Competitive Landscape - The male health product segment has seen a sales volume increase of over 30%, despite a decline in sales value due to intensified competition [3] - The ninth batch of centralized procurement includes 44 generic names, with the company qualifying for 4 products and potentially 4-6 more under review [3]